Aktien Sensor

DSM-Firmenich AG is making progress on its share repurchase program, driven by the company’s goal to optimize its capital structure and capitalize on the rapidly growing global industrial enzyme market.

DSM-Firmenich AG has embarked on a strategic transformation, appointing a new president for its fine fragrance business and taking steps to optimize its financial structure and reduce debt.

DSM-Firmenich AG has taken bold steps to revamp its financial landscape by redeeming a €750 million hybrid bond and repurchasing €580 million worth of shares, signaling a commitment to financial prudence and potentially boosting investor confide…

DSM-Firmenich has partnered with Meala to commercialize texturizing protein for meat alternatives, aiming to drive innovation in the plant-based food sector.

DSM-Firmenich AG has completed the sale of its stake in Feed Enzymes Alliance, marking a significant step towards achieving its long-term goals and positioning the company for continued growth and success.

DSM-Firmenich AG has updated its share repurchase program, aiming to buy back CHF 500 million worth of shares to optimize its capital structure and return value to shareholders.

DSM-Firmenich AG has made significant progress, with shareholders approving all resolutions and the company making headway on its share repurchase program, leading to growing investor optimism and a moderate increase in share value.

DSM-Firmenich AG’s Annual General Meeting saw shareholders overwhelmingly approve resolutions, boosting investor confidence and positioning the company for long-term growth.

DSM-Firmenich AG’s Q1 2025 earnings update shows a mixed bag of numbers, but the company’s management is optimistic about its future prospects and growing global presence.

DSM-Firmenich AG has made significant strides in the nutrition, health, and beauty sectors through strategic partnerships and investments, positioning itself for continued success and growth.